Critical

Severe falciparum malaria with shock (algid malaria)

Tropical sepsis · Shock / Sepsis
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Life-threatening Plasmodium falciparum infection complicated by circulatory shock ('algid malaria'), often with concurrent Gram-negative bacteraemia, requiring parenteral artesunate, resuscitation and antibacterial cover.

Figures & algorithms

Blood film (thick & thin)
Blood film (thick & thin)

Red flags

  • Impaired consciousness (cerebral malaria)
  • Shock with high parasitaemia
  • Hypoglycaemia
  • Acidosis / rising lactate
  • Oliguria, jaundice, bleeding (multi-organ involvement)

Assessment

Differential diagnosis

  • Severe falciparum malaria (algid)
  • Concurrent bacterial (Gram-negative) sepsis
  • Other tropical sepsis (typhoid, leptospirosis)
  • Viral haemorrhagic fever
  • Dengue shock syndrome

Investigations

  • Thick and thin blood films + rapid antigen test; quantify parasitaemia
  • Blood cultures (co-existing bacteraemia common)
  • Glucose (hypoglycaemia), lactate, blood gas
  • FBC, U&E, LFTs, coagulation, G6PD if considering primaquine
  • CXR (ARDS) and fluid-responsiveness assessment

Management

  • Confirm diagnosis and severity (parasitaemia, end-organ dysfunction, shock)
  • Start IV artesunate without delay — do not wait for species confirmation if high suspicion
  • Resuscitate shock cautiously — malaria patients tolerate large fluid boluses poorly (ARDS risk); use vasopressors early
  • Add empirical broad-spectrum antibiotics for probable concurrent bacterial sepsis
  • Check and correct hypoglycaemia frequently
  • Monitor for and treat complications: cerebral malaria, AKI, ARDS, DIC, haemolysis
  • Watch for post-artesunate delayed haemolysis after treatment
  • Discuss with infectious diseases and admit to critical care

Drugs & doses

Artesunate — 2.4 mg/kg IV at 0, 12 and 24 h, then once daily (drug of choice for severe malaria)
Ceftriaxone — 2 g IV (empirical cover for co-existing Gram-negative bacteraemia)
Noradrenaline — 0.05-0.5 mcg/kg/min IV titrated to MAP ≥65 mmHg
10% glucose — IV to correct/prevent hypoglycaemia
Balanced crystalloid — cautious boluses guided by responsiveness (avoid over-filling)

Disposition

Critical care admission with infectious-diseases input; monitor for delayed haemolysis and complete the oral antimalarial course on recovery.

Complications & pitfalls

  • Cerebral malaria
  • Acute kidney injury (blackwater fever)
  • ARDS
  • Hypoglycaemia
  • DIC and delayed post-artesunate haemolysis

Exam pearls

  • Shock in falciparum malaria implies co-existing bacterial sepsis until proven otherwise — give antibiotics
  • Be conservative with fluids; these patients are prone to pulmonary oedema/ARDS
  • Artesunate is superior to quinine and should not be delayed
  • Check glucose repeatedly — hypoglycaemia is common and treatable

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.